ZoBio and Actelion Enter into Drug Discovery Collaboration
News Oct 31, 2013
Under the agreement, ZoBio will apply its proprietary TINS technology to screen a library of drug fragments for specific binding to the desired conformation of the target. When successful, ZoBio will use a variety of biophysical methods, including its novel NMR-based structural biology, to validate and provide insight into the binding mechanism of the ligands.
Gregg Siegal, CSO of ZoBio said “We are proud that Actelion, a company with such success in bringing innovative drugs to the market, has selected ZoBio as a partner. We feel that this collaboration has a great chance to succeed where others have failed.”
Comments | 0 ADD COMMENT
Orphan Drugs and Rare Diseases Global Congress 2017 USA
Sep 12 - Sep 14, 2017